Subscribe
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
By Wayne Kuznar
Lung Cancer
TON - October 2019, Vol 12, No 5
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with ROS1 rearrangement, induced a response in 9 of 11 patients with TKI-naïve, ROS1-fusion–positive non–small-cell lung cancer (NSCLC). Read More ›
Osimertinib plus Savolitinib Promising for Non–Small-Cell Lung Cancer with MET-Driven Resistance
Osimertinib plus Savolitinib Promising for Non–Small-Cell Lung Cancer with MET-Driven Resistance
By Phoebe Starr
Lung Cancer
TON - June 2019, Vol 12, No 3
Atlanta, GA—The combination of the investigational MET inhibitor savolitinib plus the EGFR inhibitor osimertinib (Tagrisso) achieved encouraging responses in patients with MET-amplified, EGFR-positive non–small-cell lung cancer (NSCLC) and acquired, MET-driven resistance to previous therapies, with an acceptable side-effect profile. These findings represent interim results of 2 expansion cohorts of a phase 1b clinical trial presented at the 2019 American Association for Cancer Research meeting. Read More ›
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Non–Small-Cell Lung Cancer
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Non–Small-Cell Lung Cancer
By Phoebe Starr
Lung Cancer
TON - June 2019, Vol 12, No 3
Atlanta, GA—Immune checkpoint inhibitors represent a tremendous advance in the treatment of several types of cancers. Although approximately 20% to 25% of patients will have durable responses with these agents, it has been challenging to find biomarkers to identify who these patients are. Read More ›
Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation
By Loretta Fala, Medical Writer
FDA Updates, Lung Cancer
2019 Fourth Annual Oncology Guide to New FDA Approvals
Lung and bronchus cancer, the second most common form of cancer, accounts for 13.5% of all new cancer cases in the United States. In 2018 alone, lung cancer was newly diagnosed in 234,030 individuals and accounted for 154,050 deaths. In fact, lung cancer is the leading cause of cancer-related mortality in men and women, and is responsible for more than 25% of all cancer deaths. The 5-year survival rate for patients whose lung cancer has spread regionally (to regional lymph nodes) is 29.7%, but that survival rate is only 4.7% for patients with distant metastases. Read More ›
Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation
By Loretta Fala, Medical Writer
FDA Updates, Lung Cancer
2019 Fourth Annual Oncology Guide to New FDA Approvals
Lung and bronchus cancer is the second most common form of cancer in the United States. In 2018, lung cancer was newly diagnosed in 234,030 individuals, representing 13.5% of all new cancer cases. Lung cancer remains the leading cause of cancer mortality in men and women, accounting for more than 25% of all cancer deaths, which translated to 154,050 deaths in 2018. The relative 5-year survival rate for metastatic lung cancer is only 4.7%. Read More ›
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
By Lisa A. Raedler, PhD, RPh, Medical Writer
FDA Updates, Lung Cancer
2018 Third Annual Oncology Guide to New FDA Approvals

The FDA accelerated the approval of brigatinib (Alunbrig), a new generation of oral ALK inhibitor, for the treatment of patients with ALK-positive metastatic NSCLC who do not tolerate or have had an inadequate response to crizotinib..

Read More ›
Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC
Lung Cancer
Web Exclusives
A post hoc analysis of the phase 2 ALTA trial showed longer overall survival in crizotinib-refractory patients with advanced ALK-positive NSCLC who continued brigatinib versus discontinuing it after disease progression. Read More ›
CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker
Lung Cancer
Web Exclusives
In treatment-naïve patients with NSCLC and high tumor mutation burden—regardless of PD-L1 expression—the combination of nivolumab plus ipilimumab showed superior PFS versus chemotherapy in the phase 3 CheckMate-227 trial. Read More ›

Page 19 of 24


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.